The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Severe Acute Respiratory-Syndrome Treatment Market Evolve From 2026 To 2030?
The severe acute respiratory-syndrome treatment market size has seen significant expansion in recent years. It is projected to increase from $3.94 billion in 2025 to $4.53 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 15.2%. This historical growth can be attributed to factors such as outbreaks of SARS-CoV and MERS-CoV, the expansion of hospital-based treatment options, regulatory approvals for antiviral medications, an increase in intensive care unit (ICU) capacity, and various awareness campaigns.
The severe acute respiratory-syndrome treatment market size is projected to experience significant expansion over the next few years. It is forecast to reach $8.33 billion by 2030, with a compound annual growth rate (CAGR) of 16.4%. The expansion during this period is driven by factors such as AI-assisted treatment protocols, the development of novel antivirals, telemedicine-enabled critical care, global pandemic preparedness programs, and investment in rapid diagnostics and treatment monitoring. Significant trends expected in the forecast period include antiviral drug therapies, monoclonal antibodies, convalescent plasma therapy, tele-ICU integration, and AI-based treatment monitoring.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13027&type=smp
What Key Drivers Are Influencing The Growth Of The Severe Acute Respiratory-Syndrome Treatment Market?
The increasing occurrence of respiratory ailments is anticipated to drive expansion in the severe acute respiratory syndrome treatment market moving ahead. Respiratory diseases encompass a category of health conditions impacting the respiratory system, which manages respiration and the interchange of gases between the organism and its surroundings. In cases of respiratory diseases, severe acute respiratory syndrome treatment is employed to ease symptoms, avert respiratory failure, diminish inflammation, and sustain adequate oxygen levels. An illustrative example, as reported by the National Library of Medicine, a US-based medical library, in December 2023, indicates that the global count of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and older is predicted to climb by 23% by 2050, totaling nearly 600 million. Consequently, the rising prevalence of respiratory diseases is fueling the expansion of the severe acute respiratory syndrome treatment market.
Which Segment Areas Are Covered In The Severe Acute Respiratory-Syndrome Treatment Market Analysis?
The severe acute respiratory-syndrome treatment market covered in this report is segmented –
1) By Drug Class: Antibiotics, Antiviral, Corticosteroids, Monoclonal Antibodies, Other Drug Classes
2) By Route Of Administration: Oral, Intravenous
3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV), Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-2)
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Antiviral: Nucleoside Analogs, Protease Inhibitors
3) By Corticosteroids: Systemic Corticosteroids, Inhaled Corticosteroids
4) By Monoclonal Antibodies: Neutralizing Antibodies, Non-Neutralizing Antibodies
5) By Other Drug Classes: Immunomodulators, Supportive Medications
How Are Trends Impacting The Severe Acute Respiratory-Syndrome Treatment Market?
Leading companies within the severe acute respiratory syndrome treatment market are prioritizing technological innovations, particularly oral antiviral treatments engineered to hinder viral replication and lessen disease severity. This focus addresses the increasing demand spurred by repeated coronavirus outbreaks and the pressing requirement for efficient outpatient remedies. An example of this is the introduction of Ensitrelvir in September 2025 by Shionogi & Co., Ltd., a pharmaceutical firm based in Japan. This drug marks the inaugural oral antiviral therapy sanctioned for both preventing and treating SARS-CoV infections. Ensitrelvir operates by specifically obstructing the 3C-like protease, a crucial enzyme for viral reproduction, providing a precise action that diminishes viral load and alleviates symptoms more efficiently than conventional supportive care. Its formulation allows for simple oral intake, thereby facilitating broader public availability and prompt intervention to avert serious disease escalation. Such an innovation signifies a significant leap forward in SARS management amidst changing viral variants and healthcare necessities.
Which Global Companies Are Actively Competing In The Severe Acute Respiratory-Syndrome Treatment Market?
Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, AstraZeneca plc, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero Labs Ltd., Alexion Pharmaceuticals Inc., Cadila Healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, Panacea Biotec Limited, CureVac N.V., Inovio Pharmaceuticals Inc., Chimerix Inc.
Read the full severe acute respiratory-syndrome treatment market report here:
Which Region Is Expected To Register The Fastest Growth In The Severe Acute Respiratory-Syndrome Treatment Market?
North America was the largest region in the severe acute respiratory syndrome treatment market in 2025. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the severe acute respiratory-syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Severe Acute Respiratory-Syndrome Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13027&type=smp
Browse Through More Reports Similar to the Global Severe Acute Respiratory-Syndrome Treatment Market 2026, By The Business Research Company
Acute Respiratory Distress Syndrome Ards Global Market Report
Respiratory Disease Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report
Hospice Care Global Market Report
https://www.thebusinessresearchcompany.com/report/hospice-care-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model